References
- 1. Kaufman E, Liska D, Rubinshteyn V, Nandakumar G. Clostridium difficile bacteremia. Surg Infect (Larchmt). 2013 Dec;14(6):559-60.10.1089/sur.2013.055
- 2. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390–7.10.1056/NEJM200002103420604
- 3. Bignardi GE.Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40:1-15.10.1016/S0195-6701(98)90019-6
- 4. Søes LM, Holt HM, Böttiger B, Nielsen HV, Andreasen V, Kemp M, Olsen KE, Ethelberg S, Mølbak K. Risk factors for Clostridium difficile infection in the community: a case-control study in patients in general practice, Denmark, 2009-2011. Epidemiol Infect. 2014 Jul;142(7):1437-48.10.1017/S095026881300238024073613
- 5. Gryboski JD.Clostridium difficile in inflammatory bowel disease relapse.J Pediatr Gastronterol Nutr 1991;13:39-41.10.1097/00005176-199107000-000071919950
- 6. Farne HA, Martin NK, Main J, Orchard T, Tyrrell-Price J. C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection. Eur J Gastroenterol Hepatol. 2013 Jan;25(1):33-6.10.1097/MEG.0b013e328359ed6c23026925
- 7. Dupont HL. Diagnosis and management of Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1216-23.10.1016/j.cgh.2013.03.01623542332
- 8. Kingham JG, Parker DR. The association between primary biliary cirrhosis and celiac disease: a study of relative prevalences. Gut. 1998;42(1):120–12210.1136/gut.42.1.12017269399518232
- 9. Dickey W, McMillan SA, Callender ME. High prevalence of celiac sprue among patients with primary biliary cirrhosis. J Clin Gastroenterol. 1997;25(1):328–329.10.1097/00004836-199707000-000069412913
- 10. Sorensen HT, Thulstrup AM, Blomqvist P, Norgaard B, Fonager K, Ekbom A. Risk of primary biliary cirrhosis in patients with celiac disease: Danish and Swedish cohort data. Gut. 1999;44(5):736–73810.1136/gut.44.5.736172748110205215
- 11. Gillett HR, Cauch-Dudek K, Jenny E, Heathcote EJ, Freeman HJ. Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis. Can J Gastroenterol. 2000;14(8):672–675.10.1155/2000/934709
- 12. Volta U, Rodrigo L, Granito A, et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol. 2002;97(10):2609–2613.10.1111/j.1572-0241.2002.06031.x
- 13. Floreani A, Betterle C, Baragiotta A, et al. Prevalence of celiac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult celiac disease patients in Italy. Dig Liver Dis. 2002;34(4):258–26110.1016/S1590-8658(02)80145-1
- 14. Bizzaro N, Villalta D, Tonutti E, et al. IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis. Dig Dis Sci. 2003;48(12):2360–2365.10.1023/B:DDAS.0000007875.72256.e8
- 15. Lawson A, West J, Aithal GP, Logan RF. Autoimmune cholestatic liver disease in people with celiac disease: a population-based study of their association. Aliment Pharmacol Ther. 2005;21(4):401–40510.1111/j.1365-2036.2005.02328.x15709990
- 16. Hay JE, Wiesner RH, Shorter RG, LaRusso NF, Baldus WP. Primary sclerosing cholangitis and celiac disease. A novel association. Ann Intern Med. 1988;109(9): 713–717.10.7326/0003-4819-109-9-7133190057
- 17. Freeman HJ, Kwan WC. Occult celiac disease associated with lymphocytic sclerosing cholangitis. Can J Gastroenterol. 1994; 8:249–252.10.1155/1994/597238
- 18. Venturini I, Cosenza R, Miglioli L, et al. Adult celiac disease and primary sclerosing cholangitis: two case reports. Hepatogastroenterology. 1998;45(25): 2344–2347.
- 19. Wurm P, Dixon AD, Rathbone BJ. Ulcerative colitis, primary sclerosing cholangitis and celiac disease: two cases and review of the literature. Eur J Gastroenterol Hepatol. 2003;15(7):815–817.
- 20. Al-Osaimi AM, Berg CL. Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature. Dig Dis Sci. 2004;49(3):438–443.10.1023/B:DDAS.0000020499.88546.61
- 21. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345–5110.1016/j.cgh.2006.12.02817368234
- 22. Powell N, Jung SE, Krishnan B. Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent? Gut 2008; 57: 1183–4
- 23. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307–17.10.1038/nature10209320466521677747
- 24. Heikius B, Niemela S, Lehtola J,Karttunen T, Lahde S.Hepatobiliary and coexisting pancreatic duct abnomarmalities in patients with inflammatory bowel disease.Scand J Gastroenterol 1997;32:153-61.10.3109/003655297090001869051876
- 25. Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 200910.1016/j.jpeds.2008.12.03919230908
- 26. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322–3110.1111/j.1365-2036.2011.04661.x21517920
- 27. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010; 55: 415–20.10.1007/s10620-009-0749-919255850